Conference Coverage

Study: No link between vaccines, inhibitor development


 

FROM EAHAD 2017

The administration of pediatric vaccinations in close proximity to factor VIII (FVIII) exposure was not associated with inhibitor development in previously untreated patients with severe hemophilia A in the PedNet Registry.

Vaccine syringe copyright luiscar/Thinkstock
Of 232 patients from the registry who received vaccinations within 48 hours before or 24 hours after FVIII exposure, 38 (16.4%) developed inhibitors, compared with 39 (27.3%) of 143 who did not receive vaccinations within that time frame (adjusted hazard ratio for any inhibitor development related to vaccinations in close proximity to FVIII, 0.65), according to H. Marijke van den Berg, MD of University Medical Centre, Utrecht, The Netherlands.

Similarly, no association was seen between recurrent vaccinations and inhibitor development, Dr. van den Berg reported at the annual meeting of the European Association for Haemophilia and Allied Disorders.

Inhibitor development in this patient population is a multifactorial event, but these findings show no association between vaccinations administered early in life and increased inhibitor risk, she concluded.

Dr. van den Berg received grant/research support from Bayer, Baxalta, Pfizer, CSI, and Grifols.

Recommended Reading

Inherited thrombocytopenia type is a risk factor for hematologic cancers
MDedge Pediatrics
Hemophilia drugs top Medicaid spending per prescription
MDedge Pediatrics
Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
MDedge Pediatrics
Age, not infusion frequency, affects hemophilia prophylaxis adherence
MDedge Pediatrics
Hematuria a common finding in pediatric hemophilia
MDedge Pediatrics
Early intensive prophylaxis provides better QoL in hemophilia
MDedge Pediatrics
Planning, education smooth transition to longer-acting clotting factors
MDedge Pediatrics
Calcium channel blocker reduces cardiac iron loading in thalassemia major
MDedge Pediatrics
Factor VIII microcapsules eyed for eluding neutralizing antibodies
MDedge Pediatrics
VIDEO: Hemophilia B gene therapy maintains factor IX levels averaging 28%
MDedge Pediatrics